Impact Therapeutics is a China-based biopharmaceutical company that researches and develops PARP inhibitor therapies for the treatment of cancer... Read more
Impact Therapeutics is a China-based biopharmaceutical company that researches and develops PARP inhibitor therapies for the treatment of cancer... Read more
CEO
Cai Suixiong
News
May 14, 2026
Benzinga
IMPACT Therapeutics: Precision-Drug maker Impact Therapeutics Ignites IPO Frenzy
May 05, 2026
DealStreetAsia
IMPACT Therapeutics: China's Impact Therapeutics eyes up to $117m in Hong Kong IPO
Jan 17, 2025
PR Newswire
Press Release: IMPACT Therapeutics : Senaparib Approved by NMPA for 1L Maintenance Therapy in Ovarian Cancer
Jan 17, 2025
Pharamceutical Technology
IMPACT Therapeutics: IMPACT ovarian cancer capsules authorised in China
Nov 19, 2024
DealStreetAsia
IMPACT Therapeutics: IMPACT Therapeutics bags $34.5m and 37 Greater China deals worth $1.4b
Dec 22, 2023
ChinaBio Today
IMPACT Therapeutics: Huadong to Promote Impact's PARP Inhibitor in China in $40 Million Agreement
Jun 22, 2023
Global Legal Chronicle
IMPACT Therapeutics: Impact Therapeutics' Global Partnership with Eikon Therapeutics
Jun 02, 2023
Contract Pharma
IMPACT Therapeutics: Impact Therapeutics, Eikon Partner to Develop PARP1 Selective Inhibitors
Aug 19, 2022
StreetInsider
Press Release: IMPACT Therapeutics : FDA Granted Orphan Drug Designation to IMP4297+TMZ for SCLC
Mar 14, 2022
ChinaBio Today
IMPACT Therapeutics: Shanghai Impact Closes D1 Round for Synthetic Lethality Drugs
IMPACT Therapeutics Competitors
1
2
3
4
5
6
7
8
9
10